In particular, KRAS mutation has been linked to shifts in the composition and functional state of tumor-infiltrating immune cells rather than to a uniform increase or decrease in global TIGIT/CD155 expression across the entire tissue. The gene discussed is KRAS; the disease is neoplasm.